CQN-H2SITE
29.2.2024 15:56:33 CET | Business Wire | Press release
Fourth paragraph should read: "The palladium membrane separators technology employed by H2SITE enables us to produce high-purity hydrogen suitable for fuel cell applications from blends with very low hydrogen concentrations," according to Andrés Galnares, CEO of H2SITE. "We have achieved the separation of over 97% of hydrogen at very high purity in the original gas stream while ensuring that the natural gas we deliver complies with the specifications of existing users."
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229560766/en/
The updated release reads:
H2SITE HAS COMMISSIONED A MEMBRANE SEPARATOR CAPABLE OF EXTRACTING 5 TO 20% HYDROGEN BLENDS AT +99% PURITY FROM THE GAS DISTRIBUTION NETWORK
- Located in Zamudio (Bizkaia), the separation unit is installed on a natural gas distribution network and operates with hydrogen concentrations ranging from 5 to 20%
- It’s the first installation using palladium-alloy membrane separators reaching 97% hydrogen recovery rate at +99% purity
- H2SITE has built similar units operating at high pressure levels and is developing projects at large scale in Europe.
H2SITE has successfully validated the feasibility of separating hydrogen (H2) blends ranging from 5% to 20% H2 concentration in regional distribution system operator (DSO) Nortegas' gas network, within the framework of the H2SAREA project.
The injection of hydrogen into the natural gas network is a solution that allows to leverage on existing infrastructure to transport low-carbon, renewable and pure hydrogen, provided that proper separation of this hydrogen can be carried out at the point of consumption at a limited cost.
The several million kilometers of established natural gas transport and distribution networks worldwide will be a necessary asset in the transition towards low-carbon energy sources. Through the H2SAREA project, H2SITE has demonstrated that the distribution infrastructure is compatible with the transport of blends of hydrogen and renewable natural gas, enabling the use of both pure fuels in sectors where each adds the most value thanks to our membrane separator technology.
"The palladium membrane separators technology employed by H2SITE enables us to produce high-purity hydrogen suitable for fuel cell applications from blends with very low hydrogen concentrations," according to Andrés Galnares, CEO of H2SITE. "We have achieved the separation of over 97% of hydrogen at very high purity in the original gas stream while ensuring that the natural gas we deliver complies with the specifications of existing users."
H2SITE is committed to making a significant contribution to the transition towards a cleaner and more sustainable energy matrix, aligning with Nortegas' vision for implementing advanced hydrogen solutions within the natural gas network.
Thanks to the technological validation in H2SAREA, we have taken a significant step forward in low-cost hydrogen transportation solutions.
About H2SITE
H2SITE was created in 2020 and has an exclusive technology of reactors and separators for the conversion of different feedstocks into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration for applications in salt caverns or geologic hydrogen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229560766/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom